TiGenix looks into drug partnering
Written by Alyssa Clark
The Brussels based company TiGenix is looking to sell its Dutch drug manufacturing facility located in Sittard-Green, and partner with a new company for its candidate treatment for a special disorder known to link to Crohn’s disease. TiGenix was pleased with the Dutch authorities, after they gave their permission to allow the company to continue to sell the facility, while still manufacturing its product during the selling process.
Advanced conversations are underway between TiGenix and a number of interested potential partners, over commercial rights to the Cx601 outside of Europe. U.S health regulators are also joining in on this conversation, in hopes of getting a trial run of the drug in the U.S. in the near future. Most recently, TiGenix has enrolled patients for their Phase III level of treatment. The trials or Cx601 are for the treatment of complex perianal fistulas, abnormal channels that can develop between the end of the bowel and the skin, which frequently occurs in the bowels’ of patients with Crohn’s disease.
TiGenix’s main drug ChrondoCelect (which repairs damaged cartilage in the knee) has risen by 21 percent in this quarterly trading period, in just the first nine months of 2013 alone. The company projects more than a 20 percent rise in the next full-year sales, already earning the company $4.2 million.
Driven by increased sales in the Netherlands and Belgium, TiGenix believes their products will branch into mainstream Spain and Britain by 2014.
About the Author
Alyssa Clark is the Editor of Healthcare Global
